Minakem Generic APIs Minakem Generic APIs

X

CAS 1246815-34-8 manufacturers and suppliers on PharmaCompass

PharmaCompass
CAS 1246815-34-8
Also known as: 1246815-34-8, 3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)aniline
Molecular Formula
C11H10F3N3
Molecular Weight
244.23  g/mol
InChI Key
WWTGXYAJVXKEKL-FIBGUPNXSA-N

1 2D Structure

CAS 1246815-34-8

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)aniline
2.1.2 InChI
InChI=1S/C11H10F3N3/c1-7-5-17(6-16-7)10-3-8(11(12,13)14)2-9(15)4-10/h2-6H,15H2,1H3/i1D3
2.1.3 InChI Key
WWTGXYAJVXKEKL-FIBGUPNXSA-N
2.1.4 Canonical SMILES
CC1=CN(C=N1)C2=CC(=CC(=C2)N)C(F)(F)F
2.1.5 Isomeric SMILES
[2H]C([2H])([2H])C1=CN(C=N1)C2=CC(=CC(=C2)N)C(F)(F)F
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 1246815-34-8

2. 3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)aniline

2.3 Create Date
2013-11-01
3 Chemical and Physical Properties
Molecular Weight 244.23 g/mol
Molecular Formula C11H10F3N3
XLogP32.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count1
Exact Mass244.10151206 g/mol
Monoisotopic Mass244.10151206 g/mol
Topological Polar Surface Area43.8 Ų
Heavy Atom Count17
Formal Charge0
Complexity269
Isotope Atom Count3
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Flag China
Digital Content Digital Content
URL Supplier Web Content
641569-94-0
Nilotinib
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food a...
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
641571-11-1
Nilotinib
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food a...
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Flag China
Digital Content Digital Content
URL Supplier Web Content
641569-96-2
Nilotinib
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food a...
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY